MARLBOROUGH, Mass., September 23, 2024 – Sumitomo Pharma America, Inc. (SMPA) today announced that Kenton Stewart, Senior Vice President, Head of Sales and Market Access, has been promoted to become its Chief Commercial Officer (CCO) effective October 1.

Stewart brings more than 30 years of leadership experience with commercial roles in global pharmaceutical and medical device companies. As CCO of SMPA, he will be responsible for leading sales, market access and marketing, as well as commercial excellence, and commercial operations to achieve the Company’s growth and revenue goals.

“Kenton is well regarded in the industry and has led high performing teams while demonstrating his capabilities in building and nurturing company culture,” said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. “I am confident in Kenton’s ability to lead our commercial organization through our next phase of growth and am pleased to welcome him to the SMPA leadership team.”

“It is my pleasure and privilege to lead our commercial organization and I am deeply aligned with our Company’s mission to develop novel medicines that help address unmet needs,” said Kenton Stewart, Chief Commercial Officer at SMPA. “We are one team with one mission and I look forward to continuing to partner with my colleagues to advance our business and deliver for our patients.”

Prior to joining SMPA, Stewart served as Executive Vice President, Market Access and Business Development for Urovant Sciences, Inc. He previously served as Senior Vice President, Health Systems Business Unit at Alkermes, Inc. Prior to that, Stewart had a series of leadership roles over a 12-year period at Astellas Pharma US, Inc. His professional background also includes experience with Tap Pharmaceuticals and Abbott Laboratories.

Stewart received a BBA from Wichita State University and his MBA from Bellevue University.

About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in oncology, urology, women’s health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.

SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.

© 2024 Sumitomo Pharma America, Inc. All rights reserved.